


Stabilis



Digoxin



Εμπορική ονομασία

Cardixin	Αίγυπτος
Celoxin	Ινδία
Digibind	Η.Π.Α., νέα Ζηλανδία
Digocard	Αργεντινή, Εκουαδόρ
Digosin	Ιαπωνία
Digoxin	Αργεντινή, Δανία, Εκουαδόρ, Η.Π.Α., Ιράν, Καναδάς, Μεγάλη Βρετανία, Ουγγαρία, Πολωνία, Σουηδία, Φινλανδία
Digoxina	Αργεντινή, Βενεζουέλα, Εκουαδόρ, Ισπανία, Μεξικό
Digoxine	Γαλλία, Ελβετία, Ελλάδα
Geoxin	Ινδία
Lanibos	Σαουδική Αραβία
Lanicor	Γερμανία
Lanoxin	Yhdistyneet arabiemiirikunnat, Αίγυπτος, Βέλγιο, Η.Π.Α., Ιράν, Ιρλανδία, Ιταλία, Λουξεμβούργο, Μαλαισία, Μεγάλη Βρετανία, νέα Ζηλανδία, Νορβηγία, Ολλανδία, Πορτογαλία, Σαουδική Αραβία, Χιλή
Loxinan	Μεξικό



Σταθερότητα διαλυμάτων

		2,5 µg/ml	23-26°C		48			618
		2,5 µg/ml	4°C		48			618
		50 µg/ml	23-27°C		180			4690
		50 µg/ml	3-7°C		180			4690
		2,5 µg/ml	23-26°C		48			618
		2,5 µg/ml	4°C		48			618
	RL	2,5 µg/ml	23°C-26°C		6			618



Σταθερότητα σε μίγματα

								
		125 µg/ml	22°C-23°C		Milrinone lactate : 0,1 mg/ml	4		191
		50 µg/ml	22°C-23°C		Milrinone lactate : 0,35 mg/ml	4		191



Παράγοντας που επηρεάζει τη σταθερότητα

					1269
--	--	--	--	--	------



Συμβατότητες

			
		Digoxin : 250 µg/ml Amiodarone hydrochloride : 6 mg/ml	 1611
		Digoxin : 250 µg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	 3824
		Digoxin : 250 µg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	 921
		Digoxin : 250 µg/ml Anidulafungin : 0.5 mg/ml	 1982
		Digoxin : 250 µg/ml Caffeine : 10 mg/ml	 3964
		Digoxin	 618
		Digoxin : 250 µg/ml Bivalirudin : 5 mg/ml	 1713
		Digoxin : 2 µg/ml Bretylium tosilate : 1 mg/ml	 1193
		Digoxin : 2 µg/ml Bretylium tosilate : 1 mg/ml	 1193
		Digoxin : 250 µg/ml Cefiderocol sulfate tosylate : 20 mg/mL	 4528
		Digoxin : 250 µg/ml Cefiderocol sulfate tosylate : 20 mg/mL	 4528
		Digoxin : 250 µg/ml Cefmetazole sodium : 100 mg/ml	 93
		Digoxin : 250 µg/ml Ceftaroline fosamil : 2,22 mg/ml	 3249
		Digoxin : 250 µg/ml Ceftaroline fosamil : 2,22 mg/ml	 3249
		Digoxin : 250 µg/ml Ceftaroline fosamil : 2,22 mg/ml	RL3249
		Digoxin : 250 µg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL2269

		Digoxin : 250 µg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Digoxin : 250 µg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Digoxin : 250 µg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Digoxin : 250 µg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Digoxin : 250 µg/ml		301
		Digoxin : 2.5 µg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Digoxin : 250 µg/ml Ciprofloxacin lactate : 2 mg/ml		289
		Digoxin : 50 µg/ml Cloxacillin sodium : 100 mg/ml		3012
		Digoxin : 250 µg/ml		1415
		Digoxin : 250 µg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Digoxin : 250 µg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Digoxin : 250 µg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Digoxin : 0.4 µg/ml		1338
		Digoxin : 250 µg/ml Dexmedetomidine : 4 µg/ml		1712
		Digoxin : 500 µg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Digoxin Dimenhydrinate		2087
		Digoxin : 4 µg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Digoxin : 4 µg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Digoxin : 250 µg/ml Doripenem : 5 mg/ml		2262
		Digoxin : 250 µg/ml Doripenem : 5 mg/ml		2262
		Digoxin : 250 µg/ml Famotidine		397
		Digoxin : 250 µg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Digoxin : 100 µg/ml Fentanyl citrate : 50 µg/ml		63
		Digoxin : 25 µg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Digoxin : 250 µg/ml Fluconazole : 2 mg/ml		496
		Digoxin : 50 µg/ml	RL	4603
		Digoxin : 250 µg/ml Foscarnet sodium : 24 mg/ml	Ø	73

	Digoxin	RL	618
	Digoxin : 250 µg/ml Fosfomycin : 30 mg/ml		4055
	Digoxin : 250 µg/ml Fosfomycin : 30 mg/ml		4055
	Digoxin : 25 µg/ml Furosemide : 1 mg/ml		1232
	Digoxin : 250 µg/ml Hetastarch : 60 mg/ml		1721
	Digoxin : 0,25 µg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Digoxin : 0,25 µg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Digoxin : 250 µg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Digoxin : 250 µg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Digoxin : 50 µg/ml Ketamine hydrochloride : 50 mg/ml		2109
	Digoxin : 250 µg/ml Lansoprazole : 0.55 mg/ml		1625
	Digoxin : 250 µg/ml Levosimendan : 0,025 & 0,05 mg/ml		4571
	Digoxin : 1 µg/ml Lidocaine hydrochloride : 2 mg/ml	RL	619
	Digoxin : 1 µg/ml Lidocaine hydrochloride : 2 mg/ml		619
	Digoxin : 1 µg/ml Lidocaine hydrochloride : 2 mg/ml		619
	Digoxin : 250 µg/ml Linezolid : 2 mg/ml		1925
	Digoxin : 250 µg/ml Meropenem : 50 mg/ml		4319
	Digoxin : 250 µg/ml Meropenem : 1 & 50 mg/ml		266
	Digoxin : 100 µg/ml Midazolam hydrochloride : 1 mg/ml		176
	Digoxin : 50 & 125 µg/ml Milrinone lactate : 0.1 & 0.35 mg/ml		191
	Digoxin : 250 µg/ml Morphine sulfate : 1 mg/ml		62
	Digoxin : 50 µg/ml N-acetylcysteine : 200 mg/ml		3766
	Digoxin : 50 µg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Digoxin Pantoprazole sodium		2090
	Digoxin : 250 µg/ml Pethidine hydrochloride : 10 mg/ml		62
	Digoxin : 250 µg/ml Plazomicin sulfate : 24 mg/ml		4145

	Digoxin : 250 µg/ml Potassium chloride : 40 mEq/l		730
	Digoxin : 250 µg/ml Potassium chloride : 40 mEq/l	RL	730
	Digoxin : 250 µg/ml Potassium chloride : 40 mEq/l		730
	Digoxin : 250 µg/ml Propofol : 10 mg/ml	Ø	300
	Digoxin : 250 µg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Digoxin : 0,25 µg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Digoxin : 250 µg/ml Tacrolimus : 1000 µg/ml		479
	Digoxin : 250 µg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Digoxin : 250 µg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
	Digoxin : 2 µg/ml Verapamil hydrochloride : 0,08 mg/ml		706
	Digoxin		618
	Digoxin : 250 µg/ml Propofol		660
	Digoxin : 250 µg/ml Telavancin hydrochloride : 7,5 mg/ml		3254
	Digoxin : 250 µg/ml Telavancin hydrochloride : 7,5 mg/ml		3254



Τρόπος χορήγησης



Βιβλιογραφία

	τύπος	δημοσίευση
59	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	εφημερίδα	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
63	εφημερίδα	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.

73	εφημερίδα	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
93	εφημερίδα	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
176	εφημερίδα	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
191	εφημερίδα	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.
198	εφημερίδα	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
266	εφημερίδα	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	εφημερίδα	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	εφημερίδα	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	εφημερίδα	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
397	εφημερίδα	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
479	εφημερίδα	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	εφημερίδα	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
618	εφημερίδα	Shank WA, Coupal JJ. Stability of digoxin in common large-volume injections. Am J Hosp Pharm 1982 ; 39: 844-846.
619	εφημερίδα	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.

660	εφημερίδα	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
706	εφημερίδα	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
730	εφημερίδα	Allen LV, Saul Levinson R, Phisutsinhthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
921	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1058	εφημερίδα	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1193	εφημερίδα	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1201	εφημερίδα	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1232	εφημερίδα	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1269	εφημερίδα	DeMuyneck C, De Vroe C, Remon JP, Colardyn F. Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. J Clin Pharm Ther 1988 ; 13: 335-340.
1338	εφημερίδα	Baptista RJ, Dumas GJ, Bistran BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778.
1415	εφημερίδα	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1611	εφημερίδα	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	εφημερίδα	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	εφημερίδα	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	εφημερίδα	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	εφημερίδα	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	εφημερίδα	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1925	εφημερίδα	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	εφημερίδα	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	εφημερίδα	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	εφημερίδα	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	εφημερίδα	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2262	εφημερίδα	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	εφημερίδα	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	εφημερίδα	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3249	εφημερίδα	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	εφημερίδα	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	εφημερίδα	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3766	εφημερίδα	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	εφημερίδα	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	αφίσα	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	αφίσα	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	αφίσα	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuconazole sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	εφημερίδα	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.

4055	εφημερίδα	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	εφημερίδα	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	εφημερίδα	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4433	εφημερίδα	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4528	εφημερίδα	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4571	Εργαστήριο	Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics Orion Pharma 2010
4603	εφημερίδα	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4690	εφημερίδα	Friciu M, Marcelin R.B, Bédard P, Forest J.M, Leclair G. Stability of Compounded Digoxin Solution 0.05mg/mL for Injection. Hosp Pharm 2022 ; 57, 2: 294-299.
4801	εφημερίδα	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Λεξικό

	Καρδιοτονωτικό		Ενέσιμο
	Εμπορική ονομασία		Σταθερότητα διαλυμάτων
	Υποδοχέας		Μόριο Μόριο
	Συγκέντρωση		Θερμοκρασία
	Αποθήκευση		Διάρκεια σταθερότητας
	βιοϊσοδύναμα		αντικρουόμενα δεδομένα
	Βιβλιογραφία		Υαλος
	Χλωριούχο νάτριο 0,9%		Φως
	Ωρα		Προστατεύετε από το φως
	Ημέρα		Γλυκόζη 5%
RL	Γαλακτικό διάλυμα Ringer		Σταθερότητα σε μίγματα
	Διαλυτικό		Συστατικό
	Παράγοντας που επηρεάζει τη σταθερότητα		Διήθηση
	Προκαλεί		Προσρόφηση
	Συμβατότητες		Άμεση βροχόπτωση
	Ασύμβατες		Σύμφωνος
	Ουδέν		Ενέσιμο ύδωρ
	Παρεντερική θρέψη (ελεύθερο λιπιδίων)		Παρεντερική διατροφή (με λιπίδια)
	Αλλαγή χρώματος μετά από 24 ώρες		Παραγωγή φυσαλίδων αερίου
	Ειδικά διαλύτη		Καταβύθιση μετά από 4 ώρες
	Αστάθεια του γαλακτώματος μετά από 1 ώρα		Άμεση θολότητα
	Τρόπος χορήγησης		Ενδοφλέβια έκχυση
	Ενδομυϊκή		Βιβλιογραφία
	Λεξικό		